Photo from wikipedia
Abstract We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who… Click to show full abstract
Abstract We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.
Keywords:
staphylococcus aureus;
secondary therapy;
serious staphylococcus;
aureus infections;
dalbavancin secondary
Journal Title: Open Forum Infectious Diseases
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Open Forum Infectious Diseases
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!